Long-acting coagulation factors and methods of producing same

• US 9,249,407 B2
• Filed: 07/01/2013
• Issued: 02/02/2016
• Est. Priority Date: 02/03/2006
• Status: Active Grant

• Current Assignee: Opko Biologics Ltd. (Opko Health, Inc.)
• Original Assignee: Opko Biologics Ltd. (Opko Health, Inc.)
• Inventors: Fima, Udi Eyal, Hart, Gili
• Primary Examiner(s): Kemmerer, Elizabeth C
• Assistant Examiner(s): Deberry, Regina M
• Application Number:
  US13/932,839
• Publication Number:
  US 20130295072A1
• Time in Patent Office: 946 Days
• Field of Search: 514/13.7, 514/14.3, 514/9.7, 530/384, 530/381, 530/383, 530/398, 530/402
• US Class Current: 1/1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 38/4846 Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
• CPC Class Codes: C07K 14/505 Erythropoietin [EPO]
• CPC Class Codes: C07K 14/59 Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
• CPC Class Codes: C07K 14/745 Blood coagulation or fibrinolysis factors
• CPC Class Codes: C07K 2319/31 fusions, other than Fc, for prolonged plasma life, e.g. albumin
• CPC Class Codes: C12N 9/6437 Coagulation factor VIIa (3.4.21.21)
• CPC Class Codes: C12N 9/644 Coagulation factor IXa (3.4.21.22)
• CPC Class Codes: C12N 9/96 Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
• CPC Class Codes: C12Y 304/21021 Coagulation factor VIIa (3.4.21.21)

Abstract

Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using and producing same are also disclosed.

Claims

1. A method of reducing excessive bleeding in a subject, the method comprising the step of administering a pharmaceutical composition comprising a CTP-modified activated Factor VII (FVIIa) polypeptide to the subject, wherein said CTP-modified activated Factor VII (FVIIa) polypeptide comprises a FVII polypeptide and three to five chorionic gonadotropin carboxy terminal peptides (CTPs) attached to the carboxy terminus of said CTP-modified FVII polypeptide, thereby reducing excessive bleeding in said subject.

2. The method of claim 1, wherein the sequence of said modified Factor VII (FVII) polypeptide CTP-modified activated Factor VII (FVIIa) polypeptide is selected from the group consisting of SEQ ID NO:

25, 27, 29, and 46.

3. The method of claim 1, wherein the sequence of at least one CTP is SEQ ID NO:

1 or SEQ ID NO;

2.

4. The method of claim 1, wherein at least one CTP is glycosylated.

5. The method of claim 1, wherein at least one CTP is truncated.

6. The method of claim 1, wherein at least one CTP is attached to said activated Factor VII (FVIIa) polypeptide via a linker.

7. The method of claim 6, wherein said linker is a peptide bond.

8. The method of claim 1, wherein the subject is a human child.

9. The method of claim 1, wherein said administering is via the subcutaneous route.

10. The method of claim 1, wherein said administering is via the intravenous route.

11. The method of claim 1, wherein said subject is afflicted with hemophilia.

12. The method of claim 1, wherein said subject is afflicted with vitamin K deficiency.

13. The method of claim 1, wherein said polypeptide further comprises a signal peptide.

14. The method of claim 13, wherein said signal peptide is set forth in SEQ ID NO:

47.

15. A method of reducing excessive bleeding in a subject, the method comprising the step of administering to the subject a pharmaceutical composition comprising a CTP-modified Factor IX (FIX) polypeptide, wherein said CTP-modified Factor IX (FIX) polypeptide comprises a FIX polypeptide and three to five chorionic gonadotropin carboxy terminal peptides (CTPs) attached to the carboxy terminus of said CTP-modified Factor IX (FIX) polypeptide, thereby reducing excessive bleeding in said subject.

16. The method of claim 15, wherein the sequence of said CTP-modified coagulation factor polypeptide is SEQ ID NO:

31.

17. The method of claim 15, wherein the sequence of at least one CTP is ID NO:

1 or SEQ ID NO;

2.

18. The method of claim 15, wherein at least one CTP is glycosylated.

19. The method of claim 15, wherein at least one CTP is truncated.

20. The method of claim 15, wherein at least one CTP is attached to said Factor IX (FIX) polypeptide via a linker.

21. The method of claim 15, wherein said linker is a peptide bond.

22. The method of claim 15, wherein the subject is a human child.

23. The method of claim 15, wherein said administering is via the subcutaneous route.

24. The method of claim 15, wherein said administering is via the intravenous route.

25. The method of claim 15, wherein said subject is afflicted with hemophilia B.